share_log

Virpax Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Director Dhaliwal Jatinder

Virpax Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Director Dhaliwal Jatinder

Virpax制药 | 3：首次持股声明-董事 Dhaliwal Jatinder
美股SEC公告 ·  07/09 16:06

Moomoo AI 已提取核心信息

Jatinder Dhaliwal, a director and 10% owner of Virpax Pharmaceuticals, filed an initial statement of beneficial ownership with the SEC, as per Form 3 requirements. The filing, dated July 5, 2024, indicates that Dhaliwal does not beneficially own any non-derivative or derivative securities of the company. The form, signed by attorney-in-fact Vinay Shah on behalf of Dhaliwal, was completed on July 9, 2024. This standard disclosure is part of the regulatory compliance for individuals in significant positions within publicly traded companies, ensuring transparency in ownership stakes.
Jatinder Dhaliwal, a director and 10% owner of Virpax Pharmaceuticals, filed an initial statement of beneficial ownership with the SEC, as per Form 3 requirements. The filing, dated July 5, 2024, indicates that Dhaliwal does not beneficially own any non-derivative or derivative securities of the company. The form, signed by attorney-in-fact Vinay Shah on behalf of Dhaliwal, was completed on July 9, 2024. This standard disclosure is part of the regulatory compliance for individuals in significant positions within publicly traded companies, ensuring transparency in ownership stakes.
Virpax药品公司的董事兼10%股东Jatinder Dhaliwal根据Form 3规定向SEC提交了受益所有权的初始声明。该申报文件的日期为2024年7月5日，表明Dhaliwal不存在任何该公司的非衍生或衍生证券的受益所有权。该表格由代理律师Vinay Shah代表Dhaliwal于2024年7月9日完成。这是公开交易公司内部重要职位个人监管合规的标准披露，保证公司所有权持股的透明度。
Virpax药品公司的董事兼10%股东Jatinder Dhaliwal根据Form 3规定向SEC提交了受益所有权的初始声明。该申报文件的日期为2024年7月5日，表明Dhaliwal不存在任何该公司的非衍生或衍生证券的受益所有权。该表格由代理律师Vinay Shah代表Dhaliwal于2024年7月9日完成。这是公开交易公司内部重要职位个人监管合规的标准披露，保证公司所有权持股的透明度。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间